BioServe Expands Global Customer Base

New business in second half of 2007 is a testament to the value of human bio-samples for validating diagnostic markers and drug discovery

Beltsville, MD – February 26, 2008 – BioServe today announced that in the second half of 2007 it has signed 211 agreements with leading biotechnology and pharmaceutical customers including Novartis, Sanofi - Aventis, Broad Institute, Genentech, National Cancer Institute, Baylor University and Health Canada. In addition, BioServe hit an annualized growth rate of over 300 percent from fiscal year 2006.

Since acquiring Genomics Collaborative in May 2007, BioServe has acquired 76 new customers, providing them with access to its 600,000-sample Global Repository® of well-phenotyped human DNA, serum and tissue, as well as its gene expression and biomarker validation services.

"Our performance leaves little doubt that pharmaceutical and diagnostic development has embraced the power of clinical bio-specimens for more efficient identification of new drug and diagnostic targets," said Dr. Kevin Krenitsky, Chief Executive Officer of BioServe. "To help our customers fully realize the benefits of genomics in their research and discovery efforts, BioServe offers access to the broadest spectrum of human samples - tissue, serum and DNA from globally-relevant populations - and the expertise to process those samples to identify and validate new markers."

BioServe's services platform extends from molecular research products and services, such as DNA and RNA extraction and purification reagents, DNA sequencing, oligonucleotide synthesis and genotyping to ready-made large epidemiologically sound case-control studies of diabetes, obesity and cancers including breast, prostate, lung and colorectal.

Krenitsky added, "In 2008, we are off to a strong start that will be marked by the introduction of several novel bio-sample and processing products to increase the utility and application of human bio-samples for a larger portion of the research and development community. We will continue to expand our Global Repository, and we anticipate the worldwide commercialization of BioServe's first molecular diagnostic test for colorectal cancer developed with Phenonenome Discoveries, Inc."